| First Author | Shanmugam MK | Year | 2014 |
| Journal | Cancer Lett | Volume | 346 |
| Issue | 2 | Pages | 206-16 |
| PubMed ID | 24486850 | Mgi Jnum | J:208325 |
| Mgi Id | MGI:5562938 | Doi | 10.1016/j.canlet.2014.01.016 |
| Citation | Shanmugam MK, et al. (2014) Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence. Cancer Lett 346(2):206-16 |
| abstractText | Oleanolic acid (OA, 3beta-hydroxyolean-12-en-28-oic acid) is a ubiquitous pentacyclic multifunctional triterpenoid, widely found in several dietary and medicinal plants. Natural and synthetic OA derivatives can modulate multiple signaling pathways including nuclear factor-kappaB, AKT, signal transducer and activator of transcription 3, mammalian target of rapamycin, caspases, intercellular adhesion molecule 1, vascular endothelial growth factor, and poly (ADP-ribose) polymerase in a variety of tumor cells. Importantly, synthetic derivative of OA, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), and its C-28 methyl ester (CDDO-Me) and C28 imidazole (CDDO-Im) have demonstrated potent antiangiogenic and antitumor activities in rodent cancer models. These agents are presently under evaluation in phase I studies in cancer patients. This review summarizes the diverse molecular targets of OA and its derivatives and also provides clear evidence on their promising potential in preclinical and clinical situations. |
